TD Asset Management Inc Sells 128,660 Shares of Alnylam Pharmaceuticals, Inc. $ALNY

TD Asset Management Inc trimmed its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 29.2% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 312,517 shares of the biopharmaceutical company’s stock after selling 128,660 shares during the period. TD Asset Management Inc owned 0.24% of Alnylam Pharmaceuticals worth $142,508,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Norges Bank bought a new stake in shares of Alnylam Pharmaceuticals during the 2nd quarter valued at $662,837,000. Holocene Advisors LP purchased a new position in Alnylam Pharmaceuticals during the 2nd quarter valued at about $194,616,000. Orbis Allan Gray Ltd boosted its stake in Alnylam Pharmaceuticals by 29.8% during the second quarter. Orbis Allan Gray Ltd now owns 2,121,412 shares of the biopharmaceutical company’s stock worth $691,771,000 after acquiring an additional 486,489 shares in the last quarter. Massachusetts Financial Services Co. MA purchased a new stake in Alnylam Pharmaceuticals in the third quarter worth about $162,577,000. Finally, Vanguard Group Inc. grew its holdings in Alnylam Pharmaceuticals by 2.0% in the third quarter. Vanguard Group Inc. now owns 13,565,452 shares of the biopharmaceutical company’s stock worth $6,185,846,000 after purchasing an additional 268,313 shares during the period. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have recently commented on ALNY. Morgan Stanley dropped their price target on Alnylam Pharmaceuticals from $495.00 to $408.00 and set an “equal weight” rating on the stock in a research report on Friday, January 30th. Needham & Company LLC dropped their target price on Alnylam Pharmaceuticals from $529.00 to $510.00 and set a “buy” rating on the stock in a report on Thursday, February 12th. Royal Bank Of Canada cut their target price on Alnylam Pharmaceuticals from $500.00 to $465.00 and set an “outperform” rating on the stock in a research note on Tuesday, January 20th. Jefferies Financial Group lowered their price target on Alnylam Pharmaceuticals from $550.00 to $549.00 and set a “buy” rating for the company in a research report on Thursday, October 30th. Finally, Weiss Ratings raised shares of Alnylam Pharmaceuticals from a “sell (d-)” rating to a “hold (c-)” rating in a research report on Thursday, January 15th. One investment analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and five have issued a Hold rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $477.96.

Alnylam Pharmaceuticals Trading Down 1.6%

Shares of NASDAQ:ALNY opened at $327.44 on Thursday. The company has a debt-to-equity ratio of 1.28, a current ratio of 2.76 and a quick ratio of 2.71. Alnylam Pharmaceuticals, Inc. has a 1 year low of $205.87 and a 1 year high of $495.55. The company has a market cap of $43.42 billion, a P/E ratio of 191.48 and a beta of 0.35. The stock’s fifty day moving average price is $363.18 and its 200-day moving average price is $420.28.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings data on Thursday, February 12th. The biopharmaceutical company reported $0.82 EPS for the quarter, missing the consensus estimate of $1.43 by ($0.61). The business had revenue of $1.10 billion during the quarter, compared to the consensus estimate of $1.16 billion. Alnylam Pharmaceuticals had a return on equity of 69.02% and a net margin of 6.43%.Alnylam Pharmaceuticals’s quarterly revenue was up 84.9% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.65) earnings per share. Sell-side analysts expect that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

Insider Activity

In other Alnylam Pharmaceuticals news, EVP Kevin Joseph Fitzgerald sold 2,290 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Tuesday, January 13th. The shares were sold at an average price of $370.33, for a total value of $848,055.70. Following the completion of the sale, the executive vice president owned 21,264 shares of the company’s stock, valued at approximately $7,874,697.12. The trade was a 9.72% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Jeffrey V. Poulton sold 2,780 shares of the business’s stock in a transaction on Monday, January 12th. The shares were sold at an average price of $362.87, for a total transaction of $1,008,778.60. Following the sale, the executive vice president owned 57,465 shares of the company’s stock, valued at approximately $20,852,324.55. This represents a 4.61% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 36,578 shares of company stock valued at $12,416,105 over the last three months. Corporate insiders own 1.50% of the company’s stock.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.